The approvals of the first gene and cell therapies in recent years have ushered in a new era of medicine.
These cutting-edge approaches are poised to change the trajectory of how we treat cancer, fatal genetic conditions, and other devastating diseases. But these innovations also come with their own set of challenges, including issues of access. STAT and BIORAD eBook underscores not only the promising future of gene and cell-based therapies, but also the issue that must be navigated for them to reach their full potential.
Taken together, these stories underscore not only the promising future of gene and cell-based therapies, but also the issue that must be navigated for them to reach their full potential.
The topics are:
- FDA approves first personalized cell therapy for patients with multiple myeloma
- Scientists turn to machine learning to tackle one of gene therapy’s biggest challenges
- Startup Spotlight: Encoded eyes a gene therapy for Dravet syndrome
- New rare disease gene therapy startup recruits former Sarepta executive as CEO
- Gene therapy pioneer develops a new approach to curb the side effects of treatment
- Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors
- Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
- Eliminating guesswork from AAV Gene Therapy production